Kendall Square site will allow Allergan to connect with venture capital groups and startups in Cambridge.

 Biotech business in the Boston area is booming, and another major player is taking up residence in the area. Allergan will be opening an R&D site in Kendall Square by the end of the first quarter of 2019.

The site will be run by Don Frail, Allergan’s Senior Vice President of Research, External Scientific Innovation and Nonclinical and Translational Sciences. Allergan will be joining the likes of AbbVie, Eli Lilly and Pfizer, who are already established in the area. Allergan will establish connections with proximitous startup biotechs and venture capital firms, according to the company’s Chief R&D Officer, David Nicholson.